Vericel Corp
NASDAQ:VCEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vericel Corp
NASDAQ:VCEL
|
US |
Vericel Corp
Vericel Corp makes and sells specialty cell-therapy products for difficult orthopedic and burn injuries. Its main products are used by surgeons and hospitals to treat damaged knee cartilage and severe burns, where standard treatments may not work as well. The company focuses on very specific medical problems instead of broad drug categories. Its customers are hospitals, operating rooms, orthopedic surgeons, and burn centers. Vericel earns money when these medical providers buy its approved therapies for use in patients, with payment often coming through the healthcare reimbursement system. In simple terms, it sells high-value, procedure-based treatments that are used in specialized care settings. What makes Vericel different is that it sits between drug makers and surgical care. It does not mass-market everyday medicines; it develops and manufactures living-cell products that are tied to a specific patient procedure and medical specialist. That gives it a focused role in regenerative medicine and makes its business closely linked to hospital and surgeon adoption rather than broad consumer demand.
Vericel Corp makes and sells specialty cell-therapy products for difficult orthopedic and burn injuries. Its main products are used by surgeons and hospitals to treat damaged knee cartilage and severe burns, where standard treatments may not work as well. The company focuses on very specific medical problems instead of broad drug categories.
Its customers are hospitals, operating rooms, orthopedic surgeons, and burn centers. Vericel earns money when these medical providers buy its approved therapies for use in patients, with payment often coming through the healthcare reimbursement system. In simple terms, it sells high-value, procedure-based treatments that are used in specialized care settings.
What makes Vericel different is that it sits between drug makers and surgical care. It does not mass-market everyday medicines; it develops and manufactures living-cell products that are tied to a specific patient procedure and medical specialist. That gives it a focused role in regenerative medicine and makes its business closely linked to hospital and surgeon adoption rather than broad consumer demand.
Record quarter: Vericel reported first-quarter total revenue of more than $68 million, up 30% year over year and well above guidance, with strength in both MACI and Burn Care.
Guidance raised: Management lifted full-year total revenue guidance by $10 million to $326 million to $336 million, mainly reflecting first-quarter outperformance and expected NexoBrid BARDA revenue in the second half.
MACI momentum: MACI revenue rose 22% to $56.4 million, helped by double-digit volume growth and the first quarter with the expanded sales force in its new territories.
Burn Care strength: Burn Care revenue jumped over 90% to $12 million, led by a strong Epicel quarter and early signs of broader NexoBrid adoption.
Profit and cash: Gross margin expanded to 72%, adjusted EBITDA margin reached 14%, free cash flow was $15.1 million, and the company ended with about $211 million in cash and investments.
BARDA award: Vericel said the up to $197 million BARDA award for NexoBrid should begin contributing procurement revenue in the third quarter, with about $5 million to $6 million expected in the second half.
Outlook stance: Management said it is not baking in procedure slowdown or competitive pressure into guidance and remains prudent, while still seeing room for outperformance if current trends continue.
